Roivant Sciences Ltd. (ROIV) Income Statement
ROIV FY2026 at a glance
Fiscal year ended March 31, 2026 · U.S. dollarsROIV revenue and net income
Where ROIV's revenue goes
FY2026Each bar shows an amount and its share of revenue. ROIV kept −3,629.2% of revenue as net income.
ROIV profit margins
ROIV growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −71.6% | −36.0% | −19.1% | — |
| Gross profit | −75.2% | −37.4% | −20.3% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ROIV quarterly EPS vs estimates
Roivant Sciences beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 9, 2026 (estimate $-0.52).
ROIV income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.3M | $29.1M | $32.7M | $31.5M | $55.3M | $23.8M | $67.7M | $2.3M |
| Cost of revenue | $1.3M | $911,000 | $1.6M | $3.0M | $9.0M | $2.1M | $1.1M | $606,000 |
| Gross profit | $7.0M | $28.1M | $31.1M | $28.5M | $46.3M | $21.7M | $66.6M | $1.7M |
| Research & development | $681.8M | $550.4M | $439.9M | $454.1M | $483.0M | $236.6M | $263.2M | $513.0M |
| Sales, general & admin | $610.5M | $591.4M | $416.1M | $383.4M | $775.0M | $259.9M | $335.8M | $237.2M |
| Total operating expenses | $1.29B | $1.14B | $856.0M | $837.5M | $1.26B | $1.09B | $599.0M | $750.2M |
| Operating income | −$1.29B | −$1.11B | −$824.9M | −$809.0M | −$1.21B | −$1.07B | −$532.4M | −$748.5M |
| Interest income | $178.1M | $258.4M | $146.4M | $32.2M | $369,000 | $1.4M | — | — |
| Interest expense | — | — | $34.8M | $28.0M | $7.0M | $2.8M | $7.7M | $7.5M |
| Income before taxes | −$264.6M | −$681.6M | $4.57B | −$885.0M | −$923.7M | −$898.5M | −$561.0M | −$807.2M |
| Income taxes | $133.3M | $48.2M | $21.5M | $4.1M | $369,000 | $1.7M | $7.1M | $2.6M |
| Net income | −$299.8M | −$172.0M | $4.35B | −$1.01B | −$845.3M | −$809.2M | $1.20B | −$1.04B |
| EBITDA | −$261.2M | −$667.5M | $4.62B | −$838.2M | −$910.8M | −$895.7M | −$553.3M | $138.1M |
| EPS (diluted) | −$1.09 | −$0.97 | −$0.97 | −$1.24 | −$1.28 | $0.36 | −$0.27 | — |
| Gross margin | 84.4% | 96.9% | 95.1% | 90.4% | 83.8% | 91.4% | 98.3% | 73.9% |
| Operating margin | −15,560.6% | −3,833.3% | −2,521.7% | −2,565.9% | −2,191.8% | −4,500.5% | −786.6% | −32,207.0% |
| Net margin | −3,629.2% | −592.0% | 13,294.2% | −3,200.2% | −1,528.9% | −3,400.9% | 1,773.6% | −44,835.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $2.5M | $2.0M | $1.6M | $2.2M | $7.6M | $9.0M | $4.5M | $4.5M | $28.9M | $15.6M | $3.6M |
| Cost of revenue | $284,000 | $320,000 | $700,000 | $111,000 | $154,000 | $205,000 | $259,000 | $234,000 | $234,000 | $4.4M | $197,000 | $223,000 |
| Gross profit | $1.2M | $2.2M | $1.3M | $1.5M | $2.0M | $7.4M | $8.8M | $4.2M | $4.2M | $24.5M | $15.4M | $3.4M |
| Research & development | $202.0M | $198.9M | $165.4M | $164.6M | $152.9M | $145.2M | $141.6M | $142.3M | $143.1M | $120.9M | $108.1M | $114.8M |
| Sales, general & admin | $165.5M | $158.2M | $175.1M | $143.1M | $134.0M | $148.2M | $141.5M | $204.0M | $205.4M | $197.3M | $128.2M | $88.6M |
| Total operating expenses | $367.2M | $357.2M | $340.5M | $307.7M | $286.9M | $292.3M | $283.1M | $346.0M | $346.0M | $290.5M | −$5.11B | $217.3M |
| Operating income | −$366.0M | −$355.0M | −$339.2M | −$306.2M | −$284.9M | −$285.0M | −$274.4M | −$341.7M | −$341.7M | −$266.0M | $5.13B | −$213.9M |
| Interest income | $36.9M | $41.2M | $43.3M | $45.3M | $48.3M | $54.6M | $61.9M | $69.8M | $72.1M | $83.5M | $32.0M | $14.3M |
| Interest expense | — | — | — | — | — | — | — | $13.4M | $13.4M | $7.2M | $9.4M | $9.2M |
| Income before taxes | −$294.6M | $454.1M | −$290.4M | −$159.0M | −$269.3M | −$203.1M | −$234.5M | −$224.4M | −$224.4M | −$191.5M | $5.15B | −$241.4M |
| Income taxes | −$4.0M | $98.4M | $23.3M | $7.0M | $4.6M | $49.3M | −$25.6M | $12.5M | $12.5M | −$9.0M | $22.4M | $3.2M |
| Net income | −$189.8M | $303.0M | −$265.9M | −$113.5M | −$223.4M | −$206.5M | $169.4M | −$230.2M | −$230.2M | −$151.1M | $5.10B | −$304.3M |
| EBITDA | −$294.0M | $454.7M | −$289.7M | −$158.1M | −$268.2M | −$201.6M | −$231.6M | −$222.6M | −$219.5M | −$179.1M | −$215.6M | −$194.4M |
| EPS (diluted) | −$0.45 | −$0.32 | −$0.24 | −$0.28 | −$0.25 | −$0.29 | −$0.20 | −$0.30 | −$0.18 | −$0.19 | −$0.21 | −$0.29 |
| Gross margin | 80.3% | 87.3% | 65.0% | 92.9% | 92.9% | 97.3% | 97.1% | 94.8% | 94.8% | 84.7% | 98.7% | 93.9% |
| Operating margin | −25,380.9% | −14,087.1% | −16,966.1% | −19,492.9% | −13,130.0% | −3,764.4% | −3,042.6% | −7,636.0% | −7,636.0% | −919.5% | 32,948.6% | −5,863.2% |
| Net margin | −13,164.4% | 12,023.6% | −13,301.2% | −7,225.9% | −10,292.9% | −2,727.5% | 1,878.3% | −5,143.8% | −5,143.8% | −522.3% | 32,747.6% | −8,342.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ROIV's financial statements (latest annual report filed May 20, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ROIV financial results
In fiscal year 2026 (ended March 31, 2026), Roivant Sciences reported revenue of $8.3 million, down 71.6% from the year before. It had a net loss of $299.8 million, a net profit margin of −3,629.2%. Diluted earnings per share came to −$1.09. Over five years revenue grew at an average rate of −19.1% a year.
See the ROIV stock overview for the latest quote and news, or the ROIV chart for price history and technical indicators.
ROIV income statement FAQ
What is Roivant Sciences's annual revenue?
Roivant Sciences reported total revenue of $8.3 million for fiscal year 2026, which ended on March 31, 2026. That was down 71.6% from $29.1 million the previous year.
Is Roivant Sciences profitable?
No. Roivant Sciences reported a net loss of $299.8 million in fiscal 2026, a net profit margin of −3,629.2%; its operating margin was −15,560.6%.
What is Roivant Sciences's gross margin?
Roivant Sciences's gross margin was 84.4% in fiscal 2026: for every $100 of revenue, Roivant Sciences kept $84 after the direct cost of its products and services.
How much does Roivant Sciences spend on research and development?
Roivant Sciences spent $681.8 million on research and development in fiscal 2026, 8,254.4% of revenue.
How fast is Roivant Sciences growing?
Revenue grew −19.1% a year on average over the last five fiscal years, from $23.8 million to $8.3 million.
What are Roivant Sciences's earnings per share?
Roivant Sciences earned $-1.09 per diluted share in fiscal 2026, compared with $-0.97 a year earlier.
When will Roivant Sciences report its next earnings?
Roivant Sciences is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 before the market opens.
When does Roivant Sciences's fiscal year end?
Roivant Sciences's fiscal year ends in March. The latest annual report covers the year ended March 31, 2026 and was filed on May 20, 2026.